Technology Development Recent Happenings

United States patent 10,125,172 was issued on November 13, 2018 for Conformationally stabilized RSV pre-fusion F proteins. NIAID Inventors (no longer at NIAID)

United States patent 10,160,795 was issued on December 25,2018 for Neutralizing antibodies to Ebola virus glycoprotein and their use. NIAID Inventor: Dr. Nancy Sullivan

United States patent 10,166,285 was issued on January 1, 2019 for Recombinant virus with diminished latency and methods of using same. NIAID inventor: Dr. Jeffrey I. Cohen

United States patent 10,130,700 was issued on November 20,2018 for Polyvalent influenza virus-like particles (VLPS) and use as vaccines. NIAID Inventor: Dr. Jeffrey Taubenberger

United States patent 10,160,957 was issued on December 25, 2018 for the Development of dengue virus vaccine components. NIAID inventors, Dr. Steve Whitehead, Dr. Joseph Blaney

United States patent 10,184,004 was issued on January 22, 2019 for CD47 targeted therapies for the treatment of infectious disease. NIAID Inventor: Dr. Kim Hasenkrug

NIAID and PATH (Program for Appropriate Technology in Health) signed a human research collaboration agreement (hu-RCA) for one year extension that expires on August 25, 2019. NIAID principle investigator: Thomas Nutman, PhD

NIAID and La Jolla Institute for Allergy & Immunology signed a human research collaboration agreement (hu-RCA) for Human sample sharing from MTB and helminth co-infected patients from both sides and bioinformatic analysis by LIAI. NIAID principle investigator: Thomas Nutman, PhD

NIAID and a grant from the New York Blood Center signed a research collaboration agreement (RCA-S) for the development of a recombinant vaccine against human onchocerciasis. NIAID principle investigator: Thomas Nutman, PhD

VRC, NIAID and the Weizmann Institute of Science signed a 2-way human research collaboration agreement (hu-RCA) to apply structure-based design and molecular modeling approaches to develop and test filovirus therapeutics and vaccines. NIAID principle investigator: Nancy Sullivan

NIAID and Cincinnati Children's Hospital Medical Center signed a human research collaboration agreement (hu-RCA) with Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) studying eosinophilic gastrointestinal disease. NIAID principle investigator: Dr. Amy Klion

NIAID and the Forsyth Institute signed a research collaboration agreement (RCA-S) to develop new recombinant Modified Vaccinia Ankara (rMVA) constructs that express HIV Env. Investigators from both institutions will create novel rMVA constructs for the potential to control HIV-1 infection as part of an oral vaccination strategy. NIAID principle investigator: Bernard Moss, MD, PhD

NIAID and University of Oxford signed a research collaboration agreement (RCA-S) to collaborate on a Malaria research project that isolates the monoclonal antibody and neutralizes malaria liver and blood-stage parasites. NIAID principle investigators: Peter D. Crompton , Dr. Robert Seder

The Vaccine Research Center (VRC), NIAID and Wyss Institute for Biologically Inspired Engineering at Harvard University signed a research collaboration agreement (RCA-S) to collaborate, design and test vaccines using VRC protein antigens in combination with the Wyss vaccine scaffold and adjuvant system, "omnivax." NIAID principle investigator: Barney S. Graham, MD, PhD; Dr. Michelle Crank

NIAID and Blood, CSF, synovial fluid, urine, saliva collected from Lyme disease patients under NIAID IRB approved protocols 02-I-0055 and 96-I-0052 and controls and signed a human research collaboration agreement (hu-RCA). NIAID principle investigator: Adriana R Marques, MD

NIAID and US Army Medical Research Institute of Infectious Diseases signed a research collaboration agreement (RCA-S) to develop, perform, or facilitate diverse screening efforts and methodologies to identify host factors that are essential for viral infection. Advances NIAID DCR's mission to identify molecules that will help identify or characterize host factor pathways. NIAID principle investigator: Peter B Jahrling

NIAID and DARPA Pandemic Prevention Platform initiative signed a human research collaboration agreement (hu-RCA) to develop methods to rapidly identify and characterize influenza antibodies, perform, or facilitate diverse screening efforts and methodologies to identify host factors that are essential for viral infections. Barney S. Graham, MD, PhD; Dr. Michelle Crank

NIAID and IUEM (Instituto Universitário Egas Moniz), and PLDTS (Programa de Luta contra as Doenças de Transmissão Sexual, incluindo VIH/Sida) signed a research collaboration agreement (RCA-S) to collaborate to study HIV epidemiology, drug resistance, pathogenesis, and the acute phase of HIV-2 infection. NIAID principle investigator: Klaus Strebel, PhD

NIAID and Ridgeback Biotherapeutics signed a research collaboration agreement (RCA-S) to advance the development of monoclonal antibodies against Ebola virus toward licensure for therapeutic and prophylactic use in control of outbreaks and prevention of epidemics. NIAID principle investigator: Nancy J Sullivan

NIAID and Sabin Vaccine Institute signed a research collaboration agreement (RCA-S) for the VRC to collaborate with VRC/NIAID chimpanzee adenovirus vectored Ebola and Marburg vaccines to move forward toward licensure. NIAID principle investigator: Nancy J Sullivan

NIAID and Vanderbilt University Medical Center signed a human research collaboration agreement (hu-RCA) to characterize antibodies by neutralization fingerprinting in serum samples from humans vaccinated with various influenza strains. NIAID principle investigator: Barney S. Graham, MD, PhD

NIAID and Qmenta signed a human research collaboration agreement (hu-RCA) to develop and optimize MRI-based models of clinical utility for multiple sclerosis (MS). NIAID principle investigator: Bibiana Bielekova, MD

NIH, NIAID, Vaccine Research Center (VRC) and Calder Biosciences Inc., and the University of Texas, Austin, signed a research collaboration agreement (RCA-S) and collaborate to design and test novel RSV vaccine immunogen candidates based on the RSV F protein. NIAID principle investigator: Barney S. Graham, MD, PhD

NIAID and University of Florida signed a human research collaboration agreement (hu-RCA) to define gene expressions and pathway signatures of marijuana consumption on the background of HIV infection using systems biology approach, and identify variables related to clinical symptoms, viral suppression, and chronic inflammation. NIAID principle investigator: Maureen Goodenow PhD

NIAID/VRC and Stanford University signed a research collaboration agreement (RCA-S) to identify and/or define potential transcriptomic signatures that correlate with protection from Mtb infection in the rhesus macaque model. NIAID principle investigator: Dr.Robert Seder

NIAID and Institute of Microbiology of the Federal Defense Forces signed a research collaboration agreement (RCA-S) for a Zika virus cDNA clone with GFP reporter gene. NIAID principle investigators: Alicia Brockington, MS, Alexander Pletnev,PhD, Jeffrey Cohen,MD

NIAID and USAMRIID will transfer 6 mice vaccinated with Ebola virus-GP at the IRF to facilitate the evaluation of Ebola virus-GP vaccine. Principle investigators: Dr Peter B Jahrling ; Dr Jens Holger Kuhn, MD, PhD

NIAID and USAMRIID collaborate on the project titled "Characterization of a novel tick isolate of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) in interferon (α/β) receptor knock out (IFNAR) mice." Principle investigators: Dr Peter B Jahrling ; Dr Jens Holger Kuhn, MD, PhD

Content last reviewed on